<DOC>
	<DOCNO>NCT03092102</DOCNO>
	<brief_summary>The Safety , Tolerability Pharmacokinetic Study idiopathic pulmonary fibrosis treatment drug HEC585 Healthy Male Female Subjects</brief_summary>
	<brief_title>The Safety , Tolerability Pharmacokinetic Study HEC585 Healthy Male Female Subjects</brief_title>
	<detailed_description>This double-blind , placebo-controlled , single , multiple oral dose study conduct 2 part . Part A comprise single-dose , sequential-group study incorporate food effect evaluation . Up 48 subject study 6 group ( Groups A1 A6 ) , group consist 8 subject . Each subject participate 1 treatment period reside clinical research unit ( CRU ) Day -1 ( day dose ) Day 7 ( 144 hour postdose ) , except Group A3 , participate second treatment period food effect evaluation . Each subject Group A3 participate 2 treatment period separate minimum 7 day . Dosing subject feed state Group A3 commence review safety data Group A4 . Part B comprise multiple-dose , sequential-group study . Up 36 subject study 3 group ( Groups B1 B3 ) , group consist 12 subject . Part B study may start completion Group A5 , dose equal less give Groups A1 A3 .</detailed_description>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>1 . Males female , race , 18 60 year age , inclusive , Screening . 2 . Body mass index 18.0 32.0 kg/m2 , inclusive , Screening . 3 . In good health , determine clinically significant finding medical history , physical examination , 12lead ECG , vital sign measurement , clinical laboratory evaluation ( congenital nonhemolytic hyperbilirubinemia [ eg , Gilbert 's syndrome ] acceptable ) Screening and/or Checkin assess Investigator ( designee ) . 4 . Females nonpregnant nonlactating . Females childbearing potential male subject agree use contraception . 5 . Able comprehend willing sign inform consent form ( ICF ) abide study restriction . 1 . Significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , respiratory , endocrine , psychiatric disorder , determine Investigator ( designee ) . 2 . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator ( designee ) . 3 . History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( uncomplicated appendectomy hernia repair allow ) . 4 . History alcoholism drug/chemical abuse within 2 year prior Checkin . 5 . Alcohol consumption &gt; 21 unit per week male &gt; 14 unit female . One unit alcohol equal 12 oz ( 360 mL ) beer , 1Â½ oz ( 45 mL ) liquor , 5 oz ( 150 mL wine ) , positive alcohol breath test Checkin . 6 . Positive urine drug abuse screen include cotinine Screening Checkin . 7 . Positive hepatitis B surface antigen , hepatitis C virus antibody and/or positive human immunodeficiency virus ( HIV ) test ( Appendix 3 ) . 8 . Absolute lymphocyte count lower limit normal confirm repeat . 9 . Participation clinical study involve administration investigational drug ( new chemical entity ) past 30 day 5 halflives ( know ) , whichever longer , prior Checkin . 10 . Use intend use medications/products know alter drug absorption , metabolism , elimination process , include St. John 's Wort , within 30 day prior Checkin , unless deem acceptable Investigator ( designee ) . Strong CYP3A inhibitor inducer avoid . 11 . Use intend use prescription medications/products , within 14 day prior Checkin , unless deem acceptable Investigator ( designee ) . 12 . Use intend use nonprescription medications/products include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation within 7 day prior Checkin , unless deem acceptable Investigator ( designee ) . 13 . Use tobacco nicotinecontaining product within 3 month prior Checkin . 14 . Consumption food beverage contain poppy seed , grapefruit , Seville oranges within 7 day prior Checkin , consumption caffeinecontaining food beverage within 72 hour prior Checkin , consumption alcohol within 48 hour prior Checkin . 15 . Receipt blood product within 2 month prior Checkin . 16 . Donation blood 56 day prior Screening , plasma 2 week prior Screening , platelets 6 week prior Screening . 17 . Poor peripheral venous access . 18 . Have previously complete withdrawn study , previously receive investigational product . 19 . Subjects , opinion Investigator ( designee ) , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>